Click here for slides on this topic


Artery

A blood vessel that carries blood from the heart to other parts of the body.
The following content matched the glossary term: Artery

Do statins interfere with lifestyle intervention in the prevention of diabetes in primary healthcare? One-year follow-up of the FIN-D2D project

Top

Rautio N, Jokelainen J, Oksa H, et al. Do statins interfere with lifestyle intervention in the prevention of diabetes in primary healthcare? One-year follow-up of the FIN-D2D project. BMJ Open. 2012;2(5). pii: e001472. doi: 10.1136/bmjopen-2012-001472. Treatment with statins has been linked to an increased risk for type 2 diabetes in several post-hoc evaluations of previous completed trials, leading to controversy regarding the risk/benefit profile of statin therapy for primary prevention in patients who are at low risk for developing cardiovascular (CV) events.

Facts About Hypertension

Top

 

Patient education handout that discusses the importance of hypertension control and management, hypertension risk factors, and tips for keeping blood pressure in check.

Association of weight status with mortality in adults with incident diabetes

Top

Carnethon MR, De Chavez PJ, Biggs ML, et al. Association of weight status with mortality in adults with incident diabetes. JAMA. 2012;308(6):581-590. Carnethon and colleagues analyzed data from five clinical trials to compare mortality rates among subjects who were normal weight with subjects who were overweight/obese at the time of incident adult-onset diabetes.

Sudden Cardiac Death After Myocardial Infarction in Type 2 Diabetic Patients With No Residual Myocardial Ischemia

Top

Yeung CY, Lam KS, Li SW, Lam KF, Tse HF, Siu CW. Sudden Cardiac Death After Myocardial Infarction in Type 2 Diabetic Patients With No Residual Myocardial Ischemia. Diabetes Care. 2012 Aug 8.Epub ahead of print. Diabetes mellitus (DM) is a well-established risk factor for coronary artery disease. Nonetheless, it remains unclear whether DM contributes to sudden cardiac death in patients who survive myocardial infarction (MI). The objective of this study was to compare the incidence of sudden cardiac death post-MI in diabetic and nondiabetic patients with no residual myocardial ischemia.

ORIGIN: Insulin Glargine and CVD and Other Outcomes in Dysglycemia

Top

Exclusive! Expert commentary from Silvio E. Inzucchi, MD, on the ORIGIN glargine trial. ORIGIN Trial Investigators, Gerstein HC, Bosch J, et al. ORIGIN: Insulin Glargine and CVD and Other Outcomes in Dysglycemia. N Engl J Med. 2012;367(4):319-328. The Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial is a randomized, double-blind trial with a 2X2 factorial design that enrolled 12,537 patients who were at high risk for CV events and who had IFG, IGT, or newly diagnosed diabetes

ORIGIN: Omega-3 Fatty Acid and CVD Outcomes in Patients with Dysglycemia

Top

Exclusive! Video commentary from Vivian A. Fonseca, MD. ORIGIN Trial Investigators, Bosch J, Gerstein HC, et al. ORIGIN: Omega-3 Fatty Acid and CVD Outcomes in Patients with Dysglycemia. N Engl J Med. 2012;367(4):309-318. The Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial is a randomized, double-blind trial with a 2X2 factorial design that enrolled 12,537 patients who were at high risk for CV events and who had IFG, IGT, or newly diagnosed diabetes.

American Diabetes Association 72nd Scientific Sessions Daily Coverage June 9, 2012

Top

Daily coverage of American Diabetes Association 72nd Scientific Sessions  June 9, 2012

Results from the EASIE, EUREXA, TODAY, and Diabetes Prevention Program (DPP) trials; new data on SGLT2 inhibitors for diabetes treatment, incretins for diabetes treatment, ATP-IV guideline update, and more.

 

Glycemic Control: How Low Should You Go?

Top

Glycemic Control: How Low Should You Go? NDEI Education Council Co-Chair Burton E. Sobel, MD, provides expert commentary on the debate over intensive versus somewhat less intensive glycemic control in the context of a recent study by Zhao et al assessing the impact of hypoglycemia associated with antihyperglycemic medications on vascular risk in type 2 diabetes

ADA/European Association for the Study of Diabetes (EASD) Position Statement on Hyperglycemia Management in Type 2 Diabetes

Top

Joint position statement from ADA/EASD with clinical practice recommendations for managing hyperglycemia in type 2 diabetes

Blood pressure and the risk of developing diabetes in African Americans and whites: ARIC, CARDIA, and the Framingham Heart Study

Top

Wei GS, Coady SA, Goff DC Jr, Brancati FL, Levy D, Selvin E, Vasan RS, Fox CS. Blood pressure and the risk of developing diabetes in African Americans and whites ARIC, CARDIA, and the Framingham Heart Study. Diabetes Care. 2011 Feb 23. We examined the association between high blood pressure and incident type 2 diabetes in African Americans and whites aged 35-54 years at baseline.

1 2 3 4 5 6 7 8 9 10 Next 

Slide Library Results

Search Results for: Artery Slides Found: 64
Assessing Risk for Morbidity and Mortality: Comorbidities and Other Risk Factors
Relationship Between Flow-Mediated Brachial Artery Dilation and Weight Loss After Lifestyle Modification
Changes in Flow-Mediated Brachial Artery Dilation After 6 Months of Lifestyle Modification
Effect of Diet and Exercise on Inflammatory Markers
Effect of Pioglitazone on Lipid Levels
ACP Guidelines on Management of Dyslipidemia in Type 2 Diabetes
Diabetes Is Undertreated Even When Atherosclerosis Present
Meta-Analysis: A1C and CVD in Type 2 Diabetes
CARDIA: Fast-Food Frequency and Insulin Resistance
Elective Coronary Revascularization in Patients With Type 2 Diabetes
HF in Women >=65 Yr Old Strongly Associated With Preserved LVSF
Pioglitazone Decreases Carotid IMT Independent of Glycemic Control in Patients With Type 2 Diabetes
PROactive: Objective/Endpoints
PROactive: Time to Primary Composite Endpoint
Cardiovascular Mortality in Patients With Coronary Artery Disease by BMI
Steno-2: Effect of Multifactorial Intervention on CV Events in Type 2 Diabetes
PROactive 10 Substudy: Time to CV Death, Nonfatal MIa, Nonfatal Stroke
PROactive 10 Substudy: Time to All-Cause Mortality, Nonfatal MIa, Nonfatal Stroke, or ACS
PROactive 10 Substudy: Time to First Event from MACE Endpoint
BP and Type 2 Diabetes Risk in African Americans and Whites: Design
BP and Type 2 Diabetes Risk in African Americans and Whites: Results
TINSAL-T2D Trial: Baseline Characteristics
ORIGIN Glargine Trial: Eligibility Criteria and Trial Profile
ORIGIN Omega-3 Fatty Acid Trial: Eligibility Criteria and Trial Profile
ORIGIN Omega-3 Fatty Acid Trial: Baseline Characteristics (1 of 2)
ORIGIN Omega-3 Fatty Acid Trial: Baseline Characteristics (2 of 2)
JUPITER Analysis: Do Statin Benefits Outweigh Diabetes Risk?
Pooled Analysis: Mortality Among Normal and Overweight/Obese Subjects with Diabetes
Pooled Analysis: Mortality Rates Among Normal and Overweight/Obese Subjects with Diabetes
Pooled Analysis: Mortality Higher in Normal-Weight Subjects with Diabetes
Pooled Analysis: Mortality Among Normal and Overweight/Obese Subjects with Diabetes
FIN-D2D: Statin Use at Baseline and Glucose Values at 1 Year
VADT Post-hoc Analysis: Statin Use and Artery Calcification
VADT Post-hoc Analysis: Satin Use and CAC Progression
Can Coronary Artery Calcium Predict CVD Outcomes in Type 2 Diabetes?
CAC and CVD Mortality in Type 2 Diabetes: Diabetes Heart Study
Diabetes Heart Study: CAC and CVD Mortality
Diabetes Heart Study: Odds Ratios for CVD Mortality
HPS2-THRIVE: Baseline Characteristics
CHAMPION PHOENIX: Ischemic Endpoints
ORIGIN-GRACE: Design
ORIGIN-GRACE: Primary and Secondary Outcomes
ORIGIN-GRACE: No Difference in Annualized Change in Max CIMT for 12 Carotid Artery Segments with Glargine or Omega-3 Fatty Acid
ORIGIN-GRACE: Glargine, Not Omega-3 Fatty Acid, Improves Annualized Change in Max CIMT
ORIGIN-GRACE: No Difference in Annualized Change in Max Far Wall CIMT for Glargine or Omega-3 Fatty Acid
ORIGIN-GRACE: Summary of Findings
ORIGIN-GRACE: Eligibility Criteria and Trial Profile
ESH/ESC Hypertension Guidelines: Hypertension Treatment for Clinical CV Event
ESH/ESC Hypertension Guidelines: Hypertension Treatment for Patients With Atherosclerosis, Arteriosclerosis, and PAD
Look AHEAD: No Reduction in Secondary CV Outcomes with Lifestyle Changes
Meta-Analysis: Risk for New-Onset Diabetes and CV Events with Intensive- Vs Moderate Dose Statins
ACC/AHA Cholesterol Guidelines 2013: Role of Biomarkers & Imaging Tests
ACC/AHA Cholesterol Guidelines 2013: Primary ASCVD Prevention for Individuals Not in A Statin Benefit Group
IDF 2012 Type 2 Diabetes Guidelines Blood Pressure Treatment | NDEI
IDF Type 2 Diabetes Guidelines Cardiovascular Risk | NDEI
Diabetes Pregnancy Guidelines Preconception CVD Dyslipidemia | NDEI
Statin Potency New-Onset Diabetes Risk | NDEI
Statin Potency & Type 2 Diabetes Risk | NDEI
High-Potency Statins & Increased Diabetes Risk Secondary Prevention | NDEI
Study Examines Overall Safety of Bariatric (Metabolic/Diabetes) Surgery
CHD Screening & Treatment ADA Diabetes Guidelines | NDEI PPT
ACCELERATE CETP Inhibitor Trial Ended Early Due to Futility
Testing Blood Flow ABI to Prevent Diabetic Foot Ulcers Guidelines PPT | NDEI
PAD & Diabetic Foot Ulcers Foot Care Guidelines PPT | NDEI